BTAX (Biostax) Beneish M-Score : 0.00 (As of Mar. 16, 2025)

View and export this data going back to . Start your Free Trial

What is Biostax Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

The historical rank and industry rank for Biostax's Beneish M-Score or its related term are showing as below:

During the past 12 years, the highest Beneish M-Score of Biostax was -189.89. The lowest was -1558.18. And the median was -512.22.

Biostax Beneish M-Score Historical Data

The historical data trend for Biostax's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biostax Beneish M-Score Chart

Biostax Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Beneish M-Score

Get a 7-Day Free Trial

Biostax Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
Beneish M-Score	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Biostax's Beneish M-Score

For the Biotechnology subindustry, Biostax's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Biostax's Beneish M-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biostax's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Biostax's Beneish M-Score falls into.

Biostax Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Biostax for today is based on a combination of the following eight different indices:

-4.84

0.92 * DSRI

0.528 * GMI

0.404 * AQI

0.892 * SGI

0.115 * DEPI

-4.84

0.92 *

0.528 *

0.404 *

0.892 *

0.115 *

0.172 * SGAI

4.679 * TATA

0.327 * LVGI

0.172 *

4.679 *

0.327 *

This Year (Jun24) TTM:

Last Year (Jun23) TTM:

Total Receivables was $0.00 Mil.
Revenue was 0 + 0 + 0 + 0 = $0.00 Mil.
Gross Profit was 0 + 0 + 0 + 0 = $0.00 Mil.
Total Current Assets was $0.00 Mil.
Total Assets was $0.01 Mil.
Property, Plant and Equipment(Net PPE) was $0.00 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.03 Mil.
Selling, General, & Admin. Expense(SGA) was $1.04 Mil.
Total Current Liabilities was $5.31 Mil.
Long-Term Debt & Capital Lease Obligation was $0.00 Mil.
Net Income was -0.428 + -0.353 + -1.054 + -0.389 = $-2.22 Mil.
Non Operating Income was -0.051 + -0.016 + -0.669 + 0 = $-0.74 Mil.
Cash Flow from Operations was -0.002 + -0.033 + 0.16 + 0.011 = $0.14 Mil.

Total Receivables was $0.00 Mil.
Revenue was 0 + 0 + 0 + 0 = $0.00 Mil.
Gross Profit was 0 + 0 + 0 + 0 = $0.00 Mil.
Total Current Assets was $0.02 Mil.
Total Assets was $0.76 Mil.
Property, Plant and Equipment(Net PPE) was $0.00 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.03 Mil.
Selling, General, & Admin. Expense(SGA) was $1.13 Mil.
Total Current Liabilities was $3.86 Mil.
Long-Term Debt & Capital Lease Obligation was $0.00 Mil.

1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI	=	(Receivables_t / Revenue_t)	/	(Receivables_t-1 / Revenue_t-1)
	=	(0 / 0)	/	(0 / 0)
	=		/
	=

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI	=	GrossMargin_t-1	/	GrossMargin_t
	=	(GrossProfit_t-1 / Revenue_t-1)	/	(GrossProfit_t / Revenue_t)
	=	(0 / 0)	/	(0 / 0)
	=		/
	=

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI	=	(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t)	/	(1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
	=	(1 - (0 + 0) / 0.005)	/	(1 - (0.017 + 0) / 0.759)
	=	1	/	0.977602
	=

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI	=	Sales_t	/	Sales_t-1
	=	Revenue_t	/	Revenue_t-1
	=	0	/	0
	=

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI	=	(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1))	/	(Depreciation_t / (Depreciaton_t + PPE_t))
	=	(0.026 / (0.026 + 0))	/	(0.028 / (0.028 + 0))
	=	1	/	1
	=

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI	=	(SGA_t / Sales_t)	/	(SGA_t-1 /Sales_t-1)
	=	(1.043 / 0)	/	(1.132 / 0)
	=		/
	=

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI	=	((LTD_t + CurrentLiabilities_t) / TotalAssets_t)	/	((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
	=	((0 + 5.308) / 0.005)	/	((0 + 3.861) / 0.759)
	=	1061.6	/	5.086957
	=

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA	=	(IncomefromContinuingOperations_t	-	CashFlowsfromOperations_t)	/	TotalAssets_t
	=	(NetIncome_t - NonOperatingIncome_t	-	CashFlowsfromOperations_t)	/	TotalAssets_t
	=	(-2.224 - -0.736	-	0.136)	/	0.005
	=	-324.8

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Biostax Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Biostax's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.

Biostax Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biostax Corp (OTCPK:BTAX) » Definitions » Beneish M-Score

Comparable Companies

Traded in Other Exchanges

N/A

Address

2431 Aloma Avenue, Suite 124, Winter Park, FL, USA, 32792

Website

https://www.biostaxcorp.com

Biostax Corp is a biotechnology company utilizing the Biostax Development Engine, is a developer and marketer of pharmaceutical, biotechnology and MedTech products that have a well-defined path to market. The company is focused on driving the development and commercialization of proprietary mechanisms to prevent, intercept and improve these diseases at affordable cost. It is a therapeutic and health tech agnostic, constantly seeking assets with low acquisition costs and high growth opportunities having significant clinical and commercial potential.

Executives

Glen A Farmer	officer: Chief Financial Officer	20358 SENECA MEADOWS PARKWAY, GERMANTOWN MD 20876
H. Louis Salomonsky Jr. Revocable Trust	10 percent owner	2431 ALOMA AVE, SUITE 124, WINTER PARK FL 32792
Henry Louis Salomonsky	director, 10 percent owner	2431 ALOMA AVE, SUITE 124, WINTER PARK FL 32792
Kelly O'brien Wilson	10 percent owner, officer: COO and ICEO and IP	2431 ALOMA AVE, SUITE 124, WINTER PARK FL 32792
James Norman Curley	other: Member of 10% owner group	410 DAHLIA AVE, CORONA DEL MAR CA 92625
Empower Insurance Corp Ltd	other: Member of 10% owner group	1254 LEEWARD HIGHWAY, 4 CARIBBEAN PLACE, PROVIDENCIALES W7 TKCA1ZZ
Global Reverb Corp	10 percent owner, other: Member of 10% owner group	100 S EOLA DR, UNIT 1703, ORLANDO FL 32801
Paul Puskadi	other: Member of 10% owner group	2020 TIGERTAIL BLVD, 7A, DANIA BEACH FL 33004
Deane Rhodes	other: Member of 10% owner group	9200 HALSEY CIRCLE NE, TUSCALOOSA AL 35406
Roger Dale Bozarth	other: Member of 10% owner group	9028 GREAT HERON CIR, ORLANDO FL 32836
Joel Yanowitz	other: Member of 10% owner group	100 TAMAL PLZ, SUITE 106, CORTE MADERA CA 94925
Rogoff Family Trust Dtd	other: Member of 10% owner group	20701 N SCOTTSDALE DR, ST 107-501, SCOTTSDALE AZ 85255
George Sasko	other: Member of 10% owner group	515 WESTCHESTER DR, STE D, CAMPBELL CA 95008
Raster Investments, Inc	other: Member of 10% owner group	2384 ORCHARD CREST BLVD, MANASQUAN NJ 08736
Robert Jackman Dailey	other: Member of 10% owner group	401 FIRST STREET, LOS ALTOS CA 94022